

Interview Summary	Application No.	Applicant(s)	
	10/574,875	SARAIVA ET AL.	
	Examiner	Art Unit	
	SHAIENDRA -. KUMAR	1621	

All participants (applicant, applicant's representative, PTO personnel):

(1) SHAIENDRA -. KUMAR. (3)_____.

(2) Steve Hultquist. (4)_____.

Date of Interview: 10 May 2007.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.
If Yes, brief description: _____.

Claim(s) discussed: 7-9.

Identification of prior art discussed: none.

Agreement with respect to the claims f) ☒ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Examiner's amendment was authorized to cancel claims 7-9, and to insert proper Markush language in various claims.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record

A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews

Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.

All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:

- 1) A brief description of the nature of any exhibit shown or any demonstration conducted,
- 2) an identification of the claims discussed,
- 3) an identification of the specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner,
(The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.


In re United States Patent Application of:)	Docket No.:	4258-120
Applicants:)	Examiner:	S. Kumar
MASCARENHAS SARAIVA,)		
Maria Joao, et al.)		
Application No.:)		
10/574,875)		
Date Filed:)		
April 6, 2006)		
Title:)	Customer No.:	
COMPOUNDS FOR THE)		
TREATMENT OF DISEASES)		
ASSOCIATED WITH THE)		
FORMATION OF AMYLOID)		
FIBRILS)		23448

Via facsimile To Examiner S. Kumar
(571) 273-0640

PROPOSED AMENDMENT OF CLAIMS

Please cancel claims 7-9, and amend claims 2-6, in the following listing of claims 1-9 of the application:

1. (Original) A compound of structural formula (I):



(I)

in which

R₁ is a -NR_aR_b group, where R_a and R_b, independently, are a hydrogen atom or a C₁-C₆ alkyl group; -OR_c group, where R_c is a hydrogen atom or a C₁-C₆ alkyl group; a glycosyl; a C₁-C₆ polyhydroxyalkyl; or a -NH-CH(R_d)-COOR_e group, where R_d is a

side chain of one of the 20 natural alpha-amino acids in either of their two enantiomerically pure forms L or D, and R_e is a hydrogen atom or a C_1 - C_6 alkyl group; and

R_2 is a hydrogen atom, a C_1 - C_6 alkyl group, a glycosyl; a C_1 - C_6 polyhydroxyalkyl; $-C(=O)-R_f$ group, where R_f is a C_1 - C_6 alkyl group; or a $-CH_2-COO-R_g$ group, where R_g is a hydrogen atom or a C_1 - C_6 alkyl group;

and pharmaceutically acceptable salts thereof.

2. (Currently amended) A compound according to claim 1, ~~characterised in that~~ wherein R_1 is selected from: OH, NH_2 , OMe, OEt, or a $CH(R_d)-COR_e$ group, where R_d is the side chain of glycine, alanine, leucine, valine, aspartic acid or asparagine and where R_e is H or a C_1 - C_6 alkyl group; and R_2 is selected from: H, Me, glycosyl, a $-C(=O)-R_f$ group, where R_f is a Me, Et, t-Bu group; or a $-CH_2-COO-R_g$ group, where R_g is a hydrogen atom or a t-Bu group.

3. (Currently amended) A compound according to claim 1, ~~characterised in that it is~~ selected from the ~~following compounds~~ group consisting of:

- [1] 5-(2,4-difluorophenyl)-3-iodo-salicylic acid;
- [2] ethyl 5-(2,4-difluorophenyl)-3-iodo-salicylate;
- [3] methyl 5-(2,4-difluorophenyl)-3-iodo-salicylate;
- [4] 5-(2,4-difluorophenyl)-3-iodo-salicylamide;
- [5] tert-butyl [2-aminocarbonyl-4-(2,4-difluorophenyl)-6-iodo-phenoxy]-acetate;
- [6] [2-aminocarbonyl-4-(2,4-difluorophenyl)-6-iodo-phenoxy]acetic acid;
- [7] 5-(2,4-difluorophenyl)-3-iodo-salicylic acid 1-O- β -glycoside;
- [8] ethyl 2',4'-difluoro-4-methoxy-5-iodo-[1,1']biphenyl-3-carboxylate;
- [9] 2',4'-difluoro-4-methoxy-5-iodo-[1,1']biphenyl-3-carboxylic acid;
- [10] ethyl 2',4'-difluoro-4-acetyloxy-5-iodo-[1,1']biphenyl-3-carboxylate;
- [11] 2',4'-difluoro-4-(*t*-butylcarbonyloxy)-5-iodo-[1,1']biphenyl-3-carboxylic acid;
- [12] 2',4'-difluoro-4-(ethylcarbonyloxy)-5-iodo-[1,1']biphenyl-3-carboxylic acid;
- [13] ethyl ester of N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]glycine;
- [14] N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]glycine;
- [15] N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]alanine;
- [16] N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]leucine;
- [17] N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]serine;

- [18] N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]valine;
[19] N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]-aspartic acid; and
[20] N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]asparagine.

4. (Currently amended) A method for the preparation of a compound of formula (I) according to ~~claims claim~~ claim 1, ~~characterised in that it comprises~~ comprising a step of reacting diflunisal or at least one derivatives derivative thereof with an iodination reagent.

5. (Currently amended) A method according to claim 4, ~~characterised in that~~ wherein the iodination reagent ~~may be selected from~~ is selected from the group consisting of: elemental iodine; iodide salts; ~~such as~~ sodium iodide; ~~or~~ potassium iodide; iodonium salts; ~~such as~~ iodine chloride; iodonium complexes; ~~such as~~ bis(pyridine)iodonium (I) tetrafluoroborate; ~~or~~ bis(sym-collidine)iodonium (I) hexafluorophosphate; ~~and~~ organic iodine compounds; ~~such as~~ iodobenzene diacetate; and ~~or~~ N-iodosuccinimide.

6. (Currently amended) A pharmaceutical composition containing a compound according to ~~claims claim~~ claim 1, and one or more pharmaceutically acceptable excipients.

7.-9. (Canceled)

REMARKS

By the above amendments, claims 2-6 have been placed in form for allowance and issue.

Claim 5 has been amended to set forth the selection species in Markush-type format.

The selection group in claim 5 is properly constituted. See MPEP 2173.05 (h), which provides that

"... the double inclusion of an element by members of a Markush group is not, in itself, sufficient basis for objection to or rejection of claims.... The mere fact that a compound may be embraced by more than one member of a Markush group recited in the claim does not necessarily render the scope of the claim unclear. For example, the Markush group, "selected from the group consisting